Literature DB >> 19088462

Health-related quality of life in patients with neurofibromatosis type 1. A survey of 129 Italian patients.

Yllka Kodra1, Sandra Giustini, Luigina Divona, Roberto Porciello, Stefano Calvieri, Pierre Wolkenstein, Domenica Taruscio.   

Abstract

BACKGROUND/AIMS: Neurofibromatosis type 1 (NF1), a genetic condition most commonly characterized by the presence of dermal neurofibromas and café au lait macules, has a significant impact upon quality of life (QoL). The study aimed to assess the impact of NF1 on QoL.
METHODS: A total of 129 patients with NF1 completed the study questionnaires in an Italian academic dermatological centre and a neurofibromatosis clinic at the University of Rome.
RESULTS: All domains of general-health-related QoL were affected. Patients with serious cosmetic problems reported a greater impact on the emotional domain.
CONCLUSION: In our study, the impact of the cosmetic features on QoL had the greatest importance. This survey demonstrates the usefulness of QoL measurements in supplementing clinical assessments. 2008 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2008        PMID: 19088462     DOI: 10.1159/000187594

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  28 in total

Review 1.  Quality of life in rare genetic conditions: a systematic review of the literature.

Authors:  Julie S Cohen; Barbara B Biesecker
Journal:  Am J Med Genet A       Date:  2010-05       Impact factor: 2.802

2.  CRMP2-Neurofibromin Interface Drives NF1-related Pain.

Authors:  Aubin Moutal; Li Sun; Xiaofang Yang; Wennan Li; Song Cai; Shizhen Luo; Rajesh Khanna
Journal:  Neuroscience       Date:  2018-04-12       Impact factor: 3.590

3.  The effect of estradiol, testosterone, and human chorionic gonadotropin on the proliferation of Schwann cells with NF1 +/- or NF1 -/- genotype derived from human cutaneous neurofibromas.

Authors:  Paula Pennanen; Sirkku Peltonen; Roope A Kallionpää; Juha Peltonen
Journal:  Mol Cell Biochem       Date:  2017-11-28       Impact factor: 3.396

4.  Health Survey of Adults with Neurofibromatosis 1 Compared to Population Study Controls.

Authors:  Krister W Fjermestad; Livø Nyhus; Øivind J Kanavin; Arvid Heiberg; Lise B Hoxmark
Journal:  J Genet Couns       Date:  2018-02-10       Impact factor: 2.537

5.  The impact of a mind-body program on multiple dimensions of resiliency among geographically diverse patients with neurofibromatosis.

Authors:  Emily L Zale; Catherine Pierre-Louis; Eric A Macklin; Eric Riklin; Ana-Maria Vranceanu
Journal:  J Neurooncol       Date:  2017-12-23       Impact factor: 4.130

6.  The Impact of Neurofibromatosis Type 1 on the Health and Wellbeing of Australian Adults.

Authors:  Hilda A Crawford; Belinda Barton; Meredith J Wilson; Yemima Berman; Valerie J McKelvey-Martin; Patrick J Morrison; Kathryn N North
Journal:  J Genet Couns       Date:  2015-04-19       Impact factor: 2.537

7.  Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life.

Authors:  J S Cohen; H P Levy; J Sloan; J Dariotis; B B Biesecker
Journal:  Clin Genet       Date:  2015-01-20       Impact factor: 4.438

Review 8.  Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment.

Authors:  Shreya S Bellampalli; Rajesh Khanna
Journal:  Pain       Date:  2019-05       Impact factor: 6.961

9.  Quality of Life in Adults with Neurofibromatosis 1 in Brazil.

Authors:  Natália Parenti Bicudo; Balduíno Ferreira de Menezes Neto; Lucimar Retto da Silva de Avó; Carla Maria Ramos Germano; Débora Gusmão Melo
Journal:  J Genet Couns       Date:  2016-03-05       Impact factor: 2.537

Review 10.  Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.

Authors:  Ana-Maria Vranceanu; Vanessa L Merker; Elyse Park; Scott R Plotkin
Journal:  J Neurooncol       Date:  2013-07-02       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.